Abdominal Obesity Treatment Market in Global Industry : Market Growth, Recent Trends by Regions, Type, Application and Geographical Analysis to 2017 - 2025

Researchmoz added Most up-to-date research on "Abdominal Obesity Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025" to its huge collection of research reports.

Abdominal obesity or central obesity is medical condition in which excessive fat has built up around the abdomen and stomach to that it may have a negative impact on the human health. An individual is abdominally obese if the size of their waist is more than 90 cm in males and over 84 cm in females.

The major commercially available drugs used for the treatment of abdominal obesity are as follows:
Orlistat
Lorcaserin
Phentermine-topiramate
Methamphetamine

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1376066

Phentermine
Phendimetrazine
Benzphetamine
Diethylpropion
Liraglutide

Other alternative regimens used for the treatment of abdominal obesity are as follows:
Bariatric surgery
Dietary therapy
Appetite suppressants
Physical exercise

It has been observed that unhealthy lifestyle practice and over consumption of fast foods are the major causes of abdominal obesity among population. In terms of geography, North America is the largest market for abdominal obesity treatment market due to the large base of obese patients. According to the WHO, the prevalence of obesity and overweight in the regions of the Americas is the highest followed by Europe and Eastern Mediterranean regions. Moreover, according to the Centers for Disease Control and Prevention (CDC), approximately 35% of the adult population of the U.S. is obese. However, other regions such as South East Asia, Middle East and Latin America are some of the potential market where introduction of effective novel therapies might boosts up the overall market growth of abdominal obesity treatment. Due to the significant rise in obesity and rising awareness among population, these regions are expected to be the lucrative market venture for abdominal obesity treatment.

The primary factors driving the growth of this market are increasing base of population suffering from obesity and increasing levels of awareness amongst weight conscious population. Moreover, development of safe and effective therapeutics for the treatment of abdominal obesity might contribute to the growth of the abdominal obesity treatment market. For instance, a novel anti-obesity therapeutic, Bupropion/zonisamide (planned brand name Empatic) is an investigational combination therapeutic for obesity treatment. The drug is currently at phase IIB clinical trial and is being developed by California, the U.S. based, Orexigen Therapeutics, Inc.

Make an Enquiry about TOC @ https://www.researchmoz.us/abdominal-obesity-treatment-market-global-industry-analysis-size-share-growth-trends-and-forecast-2017-2025-report.html

The drug has successfully demonstrated positive trial results compared to placebo and monotherapies. Thus, the introduction of promising drugs in this market is likely to boosts the overall abdominal obesity treatment market due to the high success and effectiveness rate of the potential molecules. Furthermore, increasing government support for developing novel therapies along with high research and development initiatives on the development of personalized medicines are also expected to fuel the growth of this market. In addition, technological breakthrough such as minimally invasive surgical devices and increased focus on retaining superior quality of life are some of the factors that might contribute to the growth of this market. However, rise in overall healthcare expenditure and side effects of the anti-obesity drugs are some of the market-restraining factors that might hinder the growth of the abdominal obesity treatment market in the near future.

Currently, the abdominal obesity treatment market is a highly attractive and promising market venture due to the high incidence rate of obesity among population. Various pharmaceutical and biotechnology companies are trying to develop novel therapeutics, which can be used for the treatment of abdominal obesity. Some of the companies involved with the development and commercialization of therapeutic products for treating abdominal obesity are Arena Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novo Nordisk A/S, Orexigen Therapeutics, Inc., Upsher-Smith Laboratories Inc. and Vivus, Inc., amongst others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:
Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us

This release was published on openPR.